Slides
Page 1
The positive trend continues – stable organic sales growth in all business areas and regions Getinge Q2 2025 Mattias Perjos, CEO Agneta Palmér, CFO
Page 2
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs July 18, 2025 Getinge │ Presentation │ Q2 Report 2025 Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales 1,9 1,2 2023 2024 -37% Q2 2022 Q2 2023 Q2 2024 65% Q2 2025 61% Capital goods Recurring revenue Q2 2022 Q2 2023 Q2 2024 67% Q2 2025 62% Rest of Portfolio High margin products Sales share in R12 figures. 1) Defined as products with adjusted gross margin higher than its Business Area in 2024; 2) Net debt/adj. EBITDA < 2.5; 3) ROIC at least > Weighted Average Cost of Capital Improvements should be achieved through balanced leverage2 and attractive long-term Return on Invested Capital3
Page 3
Key takeaways Q2 2025 Getinge │ Presentation │ Q2 Report 2025 • Net sales grew by 4.1% organically and order intake increased by 4.4% organically • Margins positively impacted by acquisitions, price and mix • The financial position remains solid 50 55 Q2 2024 Q3 2024 Q4 2024 Q1 2025 50.5 Q2 2025 0 14 15 Q2 2024 Q3 2024 Q4 2024 Q1 2025 14.2 Q2 2025 R12 Gross Margin (adj) % R12 EBITA Margin (adj) % 0 34,000 36,000 Q2 2024 Q3 2024 Q4 2024 Q1 2025 35,498 Q2 2025 R12M Net Sales, SEK M July 18, 2025
Page 4
Offering and customers • First Vasoview Hemopro 3 clinical cases successfully conducted in the U.S. Deliveries at a larger scale is expected to start in September • Extension of the Servo-c ventilator with a neonatal option in targeted markets • Paragonix celebrated its 100th kidney transplant case with the KidneyVault • Launched the heavy-duty Ultima 1600 LXP/HE-HD washer • Entered a partnership with Zimmer Biomet to support Orthopaedic Ambulatory Surgery Centers (ASC) in the US • Ramping up the XEN chemistry portfolio in the U.S. leveraging the Quadralene offering through Healthmark Sustainability and Quality • Complete Intra-Aortic Balloon catheter portfolio obtained EU MDR certificate • Positive trend in regulatory compliance (findings per audit) and field corrections (field corrections per MSEK net sales) • Online training of customers continues to increase • CO2 emissions continue to decrease Key activities and events Q2 2025 July 18, 2025 Getinge │ Presentation │ Q2 Report 2025
Page 5
Order Intake and Net Sales Bridge Q2 2024 – Q2 2025 Solid organic growth in Orders and Net Sales in all regions 66 36 8,414 Q2 2024 Acute Care Therapies -157 Life Science Surgical Workflows 8,361 Q2 2025 SEK M -0.6% +4.6% -7.0% +8.8% Organic change +4.4% 48 31 8,305 Q2 2024 Acute Care Therapies Life Science -147 Surgical Workflows 8,238 Q2 2025 SEK M -0.8% +4.0% +9.3% +2.2% +4.1% Organic change Order Intake Net Sales Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 6
Adjusted Gross Profit and EBITA Bridge Q2 2024 – Q2 2025 Margins increased in the quarter despite headwinds from tariffs and FX 19 11 4,151 Q2 2024 1 Acute Care Therapies Life Science Surgical Workflows 4,183 Q2 2025 SEK M +0.8% Adj GM, % Q2 2025 (Q2 2024) Gross Margin impact Currency Product and Geo mix Cost (incl. tariffs) Price 981 989 32 17 13 13 Q2 2024 Adj GP 43 Adj Selling Adj Admin Adj R&D -110 Other OPEX D&A Q2 2025 SEK M +0.8% 58.0 38.6 43.6 50.8 (37.9) (40.9) (50.0)(58.7) 11.8% 12.0% +1.3 pp Adj GP -0.4 pp Adj OPEX +0.2 pp D&A -0.9 pp FX Adjusted Gross Profit Adjusted EBITA Margin development Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 7
Restatement: With current tariff levels, Getinge expects to reach the target of >12% average annual growth in adjusted EPS 2024-2028 Tariffs having a material impact on adjusted EBITA Impact from tariffs in Q2 July 18, 2025 Getinge │ Presentation │ Q2 Report 2025 Reminder from the Q1 presentation Impact on adj EBITA in Q2 2025 -110 MSEK Approx
Page 8
Ongoing efforts to mitigate negative impact from tariffs Working in parallel tracks with different characteristics and effects Pricing activities continue, but not possible to transfer the entire tariff effect to customers. Potential impact: + Price increases Continues in our main markets Scaling-up our ongoing productivity initiatives globally. Potential impact: ++ Cost reduction Double down on productivity Review setup for sourcing and production. Will take time to create impact. Potential impact: +++ Supply chain structure Reshape our way of working Short-medium time to implement Medium impact Medium-long time to implement High impact July 18, 2025 Getinge │ Presentation │ Q2 Report 2025
Page 9
Getinge has a solid financial position Improved FCF Y-o-Y and good safety margin on leverage despite significant acquisition FCF positively impacted by changes in receivables … 0.3 Q2 2024 0.4 Q3 2024 1.7 Q4 2024 0.2 Q1 2025 0.5 Q2 2025 +76% Free Cash Flow, SEK B … and leverage continues to be way below 2.5x 1.5 Q2 2024 2.0 Q3 2024 1.6 Q4 2024 1.4 Q1 2025 1.7 Q2 2025 1.5 2.0 1.6 1.4 1.7 Net debt/Adj EBITDA R12 (1.4x excl. pension liabilities) Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 10
Net sales for 2025 expected to increase by 2-5% organically Outlook 2025 Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 11
Summary Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 12
Key takeaways Summary Q2 2025 • Solid organic growth • Improved margins despite tariffs and negative FX • The financial position remains solid • Outlook for 2025: organic net sales growth of 2-5% Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 13
Q&A Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 14
Thank you Getinge │ Presentation │ Q2 Report 2025 July 18, 2025
Page 15
This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates. Forward looking information Getinge │ Presentation │ Q2 Report 2025 July 18, 2025